To support global pharmacovigilance services, ‘Fidelity Health Services’ is looking to expand geographical reach particularly in North America and Europe.

The company stated that the advancements in technology and its adoption in various pharmacovigilance processes have produced worthwhile results on the safety and efficacy of medicines.

Besides catering to five pharmaceutical companies and a few global CROs as their outsourcing partner for pharmacovigilance services, the company has been offering its end-to-end services for the last 5 years to one of the top generic pharmaceutical companies, empowering it to market highly valued products in 30 global markets.

The company stated that the pharmacovigilance industry has faced severe challenges, which have led to sudden myriad of disruptions in the existing and set processes, in the backdrop of the coronavirus pandemic.

The company added that it aims to hire 15-20% of new employees in operational and quality departments to fuel its expansion plans and meet the new business requirements.

The company stated that it has strong order book and considerably increased their expertise, and have a pipeline of significant new projects.

“Due to strict and severe lockdowns being imposed to constrain the spread of the virus, pharma workers and clinicians and entire healthcare industry have had limited access to facilities and change in their priorities (to stop further spread of Covid-19), resulting in the change in work routines and interruptions in regular safety inspection activities,” stated Dr. Pramod Dhembare, founder and managing partner, Fidelity Health Services.

The need for health care professionals (performing non-clinical duties) to work remotely during the pandemic has also come across as a hindrance in the steady functioning of reporting and data collecting activities in pharmacovigilance.

Dr Dhembare added, “Identifying, reporting and monitoring Adverse Drug Reactions (ADRs) has gained momentum few years back through the process of pharmacovigilance. Reporting and collection of ADRs, especially serious from patients as well as the healthcare workers precede the data analysis in pharmacovigilance, following which, the steps in the process of a product/batch recall, notification to the regulatory authority about the risk associated with drug usage and the preventive measures taken to eliminate drug-related problems take place.”